Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2025)

Historic Intangibles for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Q3 2025 value amounting to $172.9 million.

  • Ultragenyx Pharmaceutical's Intangibles rose 485.08% to $172.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.9 million, marking a year-over-year increase of 485.08%. This contributed to the annual value of $178.3 million for FY2024, which is 261.2% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Intangibles is $172.9 million, which was up 485.08% from $174.7 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Intangibles high stood at $178.3 million for Q4 2024, and its period low was $130.9 million during Q3 2021.
  • Its 5-year average for Intangibles is $158.6 million, with a median of $160.0 million in 2022.
  • Its Intangibles has fluctuated over the past 5 years, first surged by 2475.72% in 2022, then plummeted by 69.38% in 2023.
  • Ultragenyx Pharmaceutical's Intangibles (Quarter) stood at $131.3 million in 2021, then increased by 24.76% to $163.8 million in 2022, then rose by 6.11% to $173.8 million in 2023, then rose by 2.61% to $178.3 million in 2024, then dropped by 3.01% to $172.9 million in 2025.
  • Its Intangibles stands at $172.9 million for Q3 2025, versus $174.7 million for Q2 2025 and $176.5 million for Q1 2025.